Skills this job asks for
Patient careTranslationGoogle CloudCompliance
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Sanofi US Services INC paid sponsored hires in similar roles4 certified filings for “Senior Scientist” (Medical Scientists, Except Epidemiologists) in MA: $107k–$122k, median $115k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Sanofi US Services INC paid sponsored hires in similar roles
- 4 certified filings for “Senior Scientist” (Medical Scientists, Except Epidemiologists) in MA: $107k–$122k, median $115k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Job title : Global Transplant Medical Lead, HSCT
• Location: Morristown, NJ
About the Job
At Sanofi, we chase the miracles of science. Hematopoietic Stem Cell Transplantation (HSCT) represents one of medicine's most complex and frontiers, and our team is committed to advancing it.
We are seeking a Global Medical Lead, HSCT to join our growing Transplant portfolio to support the pre-launch and launch activities related to belumosudil (Rezurock). This highly visible role functions internally as the expert in Transplant to drive the development and execution of an efficient and integrated global medical/scientific strategy, including evidence generation and scientific information exchange with key stakeholders. Essential to success is an outstanding partnership with Commercial functions as well as Market Access/HEVA to maximize the value proposition. Externally, the role leads interactions with Health Care Professionals and Payers to optimize patient care and treatment outcomes through evidence-based decisions.
If you are a scientific leader with deep expertise in bone marrow transplantation and/or hematologic malignancies with a passion for translating science into meaningful patient outcomes, this is your opportunity to drive breakthroughs that could turn the impossible into possible for millions .
About Sanofi
We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people’s lives.
Main Responsibilities
• Develop and deliver the Global Medical Strategy for Belumosudil Life Cycle Management (LCM) in HSCT, ensuring alignment with overall franchise objectives and patient needs
• Serve as a key scientific expert and thought leader in HSCT, representing Sanofi at international congresses, advisory boards, and with key opinion leaders (KOLs) in the transplant and hematologic oncology community
• Build and maintain strong cross-functional partnerships with R&D, Commercial, Regulatory Affairs, Legal and other teams to ensure integrated, patient-centric decision-making
• Provide scientific and medical support for clinical trials in HSCT, including the development and implementation of Med Dev initiatives
• Drive crossfunctional strategy through participation in Global Product Teams (GPT), Medical Review Committee (MRC), and other governance bodies
• Support product launches and LCM by developing and implementing medical launch readiness plans, scientific communication strategies, and HCP engagement frameworks tailored to the transplant community
• Define and implement successful pre-launch and launch activities in cGVHD/Rezurock and prepare groundwork for possible future indications
• Develop and execute integrated communications strategies and publication planning to advance the scientific LCM narrative across the franchise
• Provide medical strategic advice/expertise for all internal stakeholders
• Provide Medical input to regulatory strategy & procedures
• Provide Medical input to product benefit-risk assessments, PBRERs and RMP
• Provide oversight for global medical studies in accordance with ICH-GCP guidelines
• Identify needs for post-marketing clinical trials and registries and supporting their management and execution
• Drive evidence generation strategies, including real-world evidence (RWE) and investigator-initiated studies (IIS) in HSCT and related hematologic conditions including the review of study outlines and protocols of global studies, country studies and review ISS requests
• Partner with Scientific Communications in the
Apply on employer site ↗